These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17483951)

  • 1. Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene.
    Bellott R; Le Morvan V; Charasson V; Laurand A; Colotte M; Zanger UM; Klein K; Smith D; Bonnet J; Robert J
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):481-8. PubMed ID: 17483951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene.
    Wu MH; Chen P; Wu X; Liu W; Strom S; Das S; Cook EH; Rosner GL; Dolan ME
    Pharmacogenetics; 2004 Sep; 14(9):595-605. PubMed ID: 15475733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
    Xu G; Zhang W; Ma MK; McLeod HL
    Clin Cancer Res; 2002 Aug; 8(8):2605-11. PubMed ID: 12171891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.
    Cecchin E; Corona G; Masier S; Biason P; Cattarossi G; Frustaci S; Buonadonna A; Colussi A; Toffoli G
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6901-7. PubMed ID: 16203781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and characterization of a human carboxylesterase 2 splice variant.
    Schiel MA; Green SL; Davis WI; Sanghani PC; Bosron WF; Sanghani SP
    J Pharmacol Exp Ther; 2007 Oct; 323(1):94-101. PubMed ID: 17636009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38.
    Charasson V; Bellott R; Meynard D; Longy M; Gorry P; Robert J
    Clin Pharmacol Ther; 2004 Dec; 76(6):528-35. PubMed ID: 15592324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haplotypes and a novel defective allele of CES2 found in a Japanese population.
    Kim SR; Sai K; Tanaka-Kagawa T; Jinno H; Ozawa S; Kaniwa N; Saito Y; Akasawa A; Matsumoto K; Saito H; Kamatani N; Shirao K; Yamamoto N; Yoshida T; Minami H; Ohtsu A; Saijo N; Sawada J
    Drug Metab Dispos; 2007 Oct; 35(10):1865-72. PubMed ID: 17640957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.
    Capello M; Lee M; Wang H; Babel I; Katz MH; Fleming JB; Maitra A; Wang H; Tian W; Taguchi A; Hanash SM
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26025324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.
    Pavillard V; Agostini C; Richard S; Charasson V; Montaudon D; Robert J
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):329-35. PubMed ID: 11914913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation and expression of aberrant methylation on irinotecan metabolic genes CES2, UGT1A1 and GUSB in the in-vitro cultured colorectal cancer cells.
    Xie FW; Peng YH; Chen X; Chen X; Li J; Yu ZY; Wang WW; Ouyang XN
    Biomed Pharmacother; 2014 Feb; 68(1):31-7. PubMed ID: 24439671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
    Rouits E; Charasson V; Pétain A; Boisdron-Celle M; Delord JP; Fonck M; Laurand A; Poirier AL; Morel A; Chatelut E; Robert J; Gamelin E
    Br J Cancer; 2008 Oct; 99(8):1239-45. PubMed ID: 18797458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Relationship between
    Ishimine M; Lee HC; Nakaoka H; Orita H; Kobayashi T; Mizuguchi K; Endo M; Inoue I; Sato K; Yokomizo T
    Dis Markers; 2018; 2018():5280736. PubMed ID: 29651325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
    Sai K; Saito Y; Tatewaki N; Hosokawa M; Kaniwa N; Nishimaki-Mogami T; Naito M; Sawada J; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Tamura T; Yamada Y; Ohe Y; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Okuda H
    Br J Clin Pharmacol; 2010 Aug; 70(2):222-33. PubMed ID: 20653675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of CES2 RNA expression in neuroblastoma.
    Uchida K; Otake K; Tanaka K; Hashimoto K; Saigusa S; Matsushita K; Koike Y; Inoue M; Ueeda M; Okugawa Y; Inoue Y; Mohri Y; Kusunoki M
    J Pediatr Surg; 2013 Mar; 48(3):502-9. PubMed ID: 23480903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
    Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
    Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis.
    Sanghani SP; Quinney SK; Fredenburg TB; Sun Z; Davis WI; Murry DJ; Cummings OW; Seitz DE; Bosron WF
    Clin Cancer Res; 2003 Oct; 9(13):4983-91. PubMed ID: 14581373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between the expression of CES2, UGT1A1, and GUSB in colorectal cancer tissues and aberrant methylation.
    Xie FW; Peng Y; Chen X; Chen X; Li J; Wang W; Yu Z; Ouyang X
    Neoplasma; 2014; 61(1):99-109. PubMed ID: 24195516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2).
    Kubo T; Kim SR; Sai K; Saito Y; Nakajima T; Matsumoto K; Saito H; Shirao K; Yamamoto N; Minami H; Ohtsu A; Yoshida T; Saijo N; Ohno Y; Ozawa S; Sawada J
    Drug Metab Dispos; 2005 Oct; 33(10):1482-7. PubMed ID: 16033949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug.
    Xiao D; Yang D; Guo L; Lu W; Charpentier M; Yan B
    Br J Pharmacol; 2013 Apr; 168(8):1989-99. PubMed ID: 23373735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.
    Merali Z; Ross S; Paré G
    Drug Metabol Drug Interact; 2014; 29(3):143-51. PubMed ID: 24988246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.